In the United States, nearly three-quarters of adults qualify as overweight or obese, 42% of whom are considered obese. The World Obesity Federation predicts that 51% of the global population will be overweight or obese by 2035.
‘Fast Company’ contributing writer Adam Bluestein joined us to break down how Novo Nordisk, the company behind Ozempic and Wegovy, developed and marketed its weight-loss drugs. He also explained why the drugs have become so popular in the U.S., how drug pricing is extremely complicated and . . . how the medications actually work to help people lose weight.
Also, we chatted with Trina Spear about how she founded Figs, a DTC healthcare apparel company.
Ozempic and Wegovy: How 2 diabetes medications became the most popular weight-loss drugs | Most Innovative Companies podcast - Listen or read transcript on Metacast
